In 2006, Takahashi and Yamanaka reported the breakthrough discovery of induction of pluripotent stem cells from fibroblasts by a combination of defined factors. Ten years later, Cell editor Joã o Monteiro brings together Shinya Yamanaka and Hans Schö ler, one the original reviewers of the landmark study, to revisit the history behind the paper and its long-lasting legacy.
Joã o Monteiro: Thanks for agreeing with identifying yourself as one of the reviewers of the 2006 iPSC paper, Hans. I was reading the paper again this morning, as well as your remarks. I feel that you were very positive about the paper from get-go, but you also had a lot of questions. In my experience, this happens very often when something is really new and it may challenge the way we think about a biological problem. What's your approach, for instance, when you're being introduced to a new concept? When you have the feeling that something will be important, but as with anything new, it will also trigger a number of questions and there will be a lot of unknowns?
Hans Schö ler: The good thing with Cell is that you can, as a referee, read the comments of the other referees as well. From that, it was pretty clear that all three of us thought that that could become a very important paper. However, you have to think back to what happened before that paper was published. That the stem cell field was coming out of a bit of a disaster because of the publication of two papers, in 2004/2005 , that we later found out to be based on fabricated data. The Yamanaka paper came to me just after that. I think all three referees, including myself, wanted to be sure that everything had been done in a way that the field could really benefit from it. We wanted the field to be convinced of how important that work was, as much as we thought it was.
What you must also realize is that I never thought-I think others didn't as well-that a combination of only transcription factors would be enough to reprogram cells. I was always thinking that you would need a combination with chromatin remodelers and all these things. Just coming up with the cocktail of those four transcription factors was kind of mind boggling. We wanted a lot of controls to strengthen the findings. I was so happy that, half a year later, three labs, including Konrad Hochedlinger, Rudolf Jaenisch and Shinya Yamanakas's lab, confirmed these data and have made this observation even stronger. It just took half a year, and the whole stem cell field was convinced.
JM: Shinya, a point that comes up often in discussions about the paper is that you took a very bold approach to the problem. While other people were looking at huge libraries and testing combinations of infinite number of molecules to try to identify factors that induced the pluripotent state, you went with a relatively small pool of highly selected candidate moleculesonly 24. Why did you take this approach?
Shinya Yamanaka: Well, actually, we did have a plan to perform a larger-scale library screening. We had isolated cDNA libraries from ES cells and also from testis, so we were planning to do that, and we had established a very sensitive assay system to perform library screening. However, before doing the actual large-scale cDNA library screening, we thought we should practice by using a smaller number of factors. At that time, we had 30 or 40 cDNAs already that we thought would be important in ES cells. We used those 24 factors just as a ''practice'' of the future large-scale cDNA libraries. To our surprise, among those 24 factors, we found the answer: the JM: That's very interesting. I didn't know that part of the story. Now that we are 10 years ahead of the publication of this first study, in retrospect, what do you think was the major contribution given by the 2006 paper? SY: Perhaps I should go back in time a bit. Our initial project was inspired by previous findings by Harold Weintraub, who showed that a single factor, MyoD, could convert fibroblasts into muscle cells, the so-called ''master gene.'' But that was just one successful case. After that, many other scientists tried to identify ''master genes'' in other tissues or organs such as the heart and the brain. Lots of these attempts failed. We kind of forgot about master transcription factors, but by publishing our ideas in the 2006 paper, we re-activated that kind of concept, the importance of transcription factors. Not just by one but a combination of a few handful of transcription factors. I thought it was a very important concept, and many other scientists started working, trying to find other combinations of transcription factors that convert one cell type to another.
Marius Wernig showed that a combination of factors can convert fibroblasts to neurons, and another colleague, Deepak Srivastava, has identified another combination of transcription factors that can convert fibroblasts to heart cells. I think our iPSC finding was a very good trigger to re-ignite that kind of research.
HS: I absolutely agree. The publication of the 2006 and 2007 Yamanaka papers has opened the minds of many researchers to see if they could find cocktails that would be able to convert somatic cells into other different cells and to understand the barriers that need to be overcome in order to obtain stem cells. The way I see it is that these efforts will continue in a way that eventually may lead us to chemical conversion of cells. You can perhaps even think about reprogramming in a way that aging or degenerative diseases, for example, could be slowed down. I think that in vitro reprogramming is an area that we will still hear a lot about in the near future.
JM: Since we are talking also about the future, can you give me your thoughts about where you see things are in terms of the potential clinical applications of this type of technology? What is looking promising in your opinion?
SY: There are two types of medical applications of iPS cells. One is regenerative medicine. The other one is drug discovery. In terms of regenerative medicine, the progress in the last 10 years has been remarkable-much faster than I anticipated 10 years ago. As a matter of fact, 2 years ago, Dr. Masayo Takahashi already started a clinical trial. So far it is only one patient, but that very first patient has been doing very well. We are now planning to expand this trial to more patients. But what we learned from the first patient, in which we performed autologous iPS cell transplantation, is that the entire process is too expensive. It also took almost a year to make iPS cells from the patient's own cells, to transfer the original cells, and to perform all the rigorous quality control tests. It was too expensive, and it took long. Instead of doing autologous transplantation, we are now planning to do allografts. We have been generating so-called iPS cell stocks from HLA homozygous donors. We have already produced clinical-grade iPS cell lines from HLA homozygous donor with the most frequent HLA haplotypes among the Japanese population. Surprisingly, just one HLA homozygous donor can cover up to 17% of all the Japanese population, so I think that's the way to go in the future because it can lower the cost tremendously and it can shorten the time of treatment. After original application, I think many other applications will be following, such as other types of transplantation, Parkinson's disease, heart disease. I think we are at the very critical point right now.
HS: Yes, I think the other thing we now can do with the iPSC technology is to better understand diseases. There are so many reports showing that you can reproduce certain aspects of a disease in the dish. Combining this, for example, with the organoids technology, you can even widen that horizon. Moreover, the advances in the CRISPR technology help us to do these experiments in a very fast way. Applying iPSC technology to drug screening is something that is done all over the world now. You can use it not only to understand disease, but also to affect certain pathways in diseases like Parkinson's. This is something that is really much closer to patients than, for example, doing model systems with animals. Both are important, of course, but now we are much closer to the human disease due to the iPSC technology.
SY: Yeah, I totally agree with Hans. When we talk about iPS cells, many laypeople and press people tend to connect iPS cells with regenerative medicine. Well, it is an important application, but I have to say that the other application, disease modeling and drug discovery using patient iPS cells, is probably at least as important as regenerative medicineprobably even more important. We have been spending a lot of time working on that aspect of iPSC applications. For example,
''I never thought-I think others didn't as well-that a combination of only transcription factors would be enough to reprogram cells.'' ''We kind of forgot about master transcription factors, but by publishing our ideas in the 2006 paper, we reactivated that kind of concept.''
we have been generating iPSCs from many rare disease patients. You know, without iPSCs, those patients felt they were kind of abandoned because very little research was being conducted on their diseases. But now that we can make iPSCs from each individual patient, we have the tools to study any disease. We can perform so-called drug repurposing. Instead of screening new chemicals, we can try existing drugs, and in many cases it does work. It will reduce the cost of drug development, and it will reduce the time required for clinical trials, I think. I hope by doing this kind of research we can help many patients suffering from rare, monogenic diseases in the near future.
HS: One important point that we should add is that this technology allows us to understand how reprogramming actually occurs. I was absolutely fascinated when Keith Campbell and Ian Wilmut published their work on Dolly, and then Teruhiko Wakayama and others did the work with mouse. I wanted to know how it is possible that you take a somatic cell nucleus, basically put it into an oocyte, and get a sheep or a mouse or other animals. We now know now that reprogramming by nuclear transfer into an oocyte and by defined factors in mature cells is not identical. There are clear differences. But the iPSC technology allows us to get an idea about how you convert a cell-a fibroblast, for example-into a pluripotent cell. And then, if you make chimeras, cell aggregation experiments, you can actually get a whole mouse. If you think about it, this is one of the most mind-boggling experiments I know of-that you have a fibroblast in a dish and then you convert this by iPSC technology into a pluripotent cell and then you can get a mouse in one step. Just think about it! This is something basic scientists-that's what I am-are really trying to understand. The technology developed by Shinya has allowed us to navigate along these lines, but many labs are still trying to understand how this works.
SY: Yeah, it's very remarkable. I think our cells are much more flexible than we previously anticipated. How surprising! That reminds me of one important point: the ethical issue. When we were trying to make iPS cells, one of our goals was to overcome ethical issues related to use of human embryonic cells, the usage of human embryos in research. We did overcome that ethical issue, but by having iPSCs, I think we are now presented with new ethical issues. For example, we can make sperm and oocyte eggs from iPSCs. From skin cells or blood cells, we can make sperm or oocyte through iPS cells. Or a breathing mouse-we can do that. Also, by injecting human iPS cells into pig or other big animals, at least in theory we can make human organs like human kidneys or human pancreas. Those kinds of research scientists have been working very hard, and it's getting closer to reality. But now the question is whether society is ready to accept that kind of new development. We really need to focus and discuss the ethical implications of any new technology, including iPS cells.
HS: We have very harsh discussions in Germany about these ethical questions. Technology suddenly allowed us to do experiments that were hard to do before. In Germany, we are still not allowed to derive human embryonic stem cells. We import embryonic stem cell lines, which were established before 2007. Newer ones we can't even import, and as I said, we can't derive our own. We have to apply for working with them. We have to submit a proposal explaining that we want to work with them. That takes a lot of time. However, we don't need to ask for permission to work with iPS cells. There have been a lot of discussions also with respect to whether you can use these cells now for reproduction. Can you have basically two iPS cell lines as father and mother, paving the way for deriving oocytes and sperm? The International Society for Stem Cell Research (ISCCR) has been discussing these issues. So have other groups. It is important that these issues are raised and that society is involved in the discussions.
JM: Do you think there are other ways to extend this discussion beyond the scientific community to include people who actually may benefit from the development of these new technologies?
HS: In Germany, we have National Ethics Committees where these questions are discussed. There are members of different churches, politicians, philosophers, and ethicists involved in these types of discussions. The National Academy of Science in Germany has also been involved and also state academies. There are publications on what we think should or should not be done.
SY: Well, one important issue is that, in order to promote that kind of discussion, scientists really need to be as transparent as possible. At the same time, we are often facing very tough races between scientists, so we cannot expose everything before publication. We are always in dilemma between being transparent and at the same time protecting the research that is still under development.
HS: Yeah, this whole field is extremely competitive. JM: I realize this is a bit of crystal ball gazing, but where do you envision that we will be in 10 years from now? SY: I have two major roles right now. One is as the director of a whole institute working on iPS cells in Kyoto, Center for iPS Cell Research and Application. So we have a common goal. We have more than 500 people, but our common goal is to bring iPS cells to patients. In this role, I'm not pure scientist. I'm more like manager to help other scientists to advance their own researches. Within the next 10 years, I really want to promote that institute so that many recent scientists can actually realize HS: Yes, I have something very complementary. I'm a Director at the Max Planck Society, and that allows me to do basic research. At the same time, I'm building an institute in Munich, with the support of the State of Bavaria, where we're trying to use iPS technology to do drug screening with disease models. This is something that I would like to continue in the future-to do something for society.
